Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History MRUS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics MRUS

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Merus BV

MRUS
Current price
52.58 USD -0.81 USD (-1.52%)
Last closed 53.82 USD
ISIN NL0011606264
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 4 008 336 128 USD
Yield for 12 month -5.62 %
1Y
3Y
5Y
10Y
15Y
MRUS
21.11.2021 - 28.11.2021

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of patients with lungs and other solid tumors; ONO-4685 to treat relapsed/refractory T cell lymphoma; and INCA33890 for advanced solid tumors. In addition, it has collaboration agreement with Eli Lilly and Company, Ono Pharmaceutical Co., Ltd., and Betta Pharmaceuticals Co. Ltd. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands. Address: Uppsalalaan 17, Utrecht, Netherlands, 3584 CT

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

90.20 USD

P/E Ratio

Dividend Yield

Financials MRUS

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures MRUS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+36 133 000 USD

Last Year

+43 947 000 USD

Current Quarter

+26 488 000 USD

Last Quarter

+9 140 000 USD

Current Year

+36 133 000 USD

Last Year

+43 947 000 USD

Current Quarter

+26 488 000 USD

Last Quarter

+9 140 000 USD
EBITDA -298 552 992 USD
Operating Margin TTM -285.94 %
Price to Earnings
Return On Assets TTM -30.61 %
PEG Ratio
Return On Equity TTM -58.66 %
Wall Street Target Price 90.20 USD
Revenue TTM 54 732 000 USD
Book Value 8.62 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 235.80 %
Dividend Yield
Gross Profit TTM -9 509 000 USD
Earnings per share -4.16 USD
Diluted Eps TTM -4.16 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin

Stock Valuation MRUS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 65.04
Price Sales TTM 73.24
Enterprise Value EBITDA -4.91
Price Book MRQ 6.72

Technical Indicators MRUS

For 52 Weeks

33.19 USD 62.98 USD
50 Day MA 49.25 USD
Shares Short Prior Month 4 650 614
200 Day MA 46.51 USD
Short Ratio 2.68
Shares Short 5 001 782
Short Percent 6.74 %